Q4 Earnings Forecast for TENX Issued By Leerink Partnrs

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Analysts at Leerink Partnrs issued their Q4 2024 EPS estimates for shares of Tenax Therapeutics in a research note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst D. Risinger expects that the specialty pharmaceutical company will earn ($1.23) per share for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($3.04) per share. Leerink Partnrs also issued estimates for Tenax Therapeutics’ Q1 2025 earnings at ($1.68) EPS, Q2 2025 earnings at ($1.92) EPS, Q3 2025 earnings at ($2.31) EPS, Q4 2025 earnings at ($2.38) EPS, FY2025 earnings at ($8.29) EPS, FY2026 earnings at ($3.91) EPS, FY2027 earnings at ($4.15) EPS and FY2028 earnings at ($2.69) EPS.

Several other analysts have also recently weighed in on the company. William Blair started coverage on Tenax Therapeutics in a report on Monday, September 30th. They set an “outperform” rating on the stock. Leerink Partners began coverage on shares of Tenax Therapeutics in a report on Thursday, October 24th. They set an “outperform” rating and a $16.00 price target on the stock. StockNews.com started coverage on Tenax Therapeutics in a research report on Thursday, September 26th. They set a “sell” rating for the company. Finally, Guggenheim began coverage on Tenax Therapeutics in a research report on Monday, October 14th. They set a “buy” rating and a $16.00 price objective for the company. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Tenax Therapeutics has an average rating of “Moderate Buy” and an average target price of $16.00.

Tenax Therapeutics Trading Down 0.8 %

Shares of TENX opened at $4.83 on Monday. Tenax Therapeutics has a 52 week low of $2.77 and a 52 week high of $33.44. The stock has a fifty day moving average of $4.02 and a 200-day moving average of $3.70.

Institutional Trading of Tenax Therapeutics

Several hedge funds have recently modified their holdings of the stock. Vestal Point Capital LP acquired a new stake in Tenax Therapeutics in the 3rd quarter valued at $288,000. Stonepine Capital Management LLC acquired a new position in shares of Tenax Therapeutics during the third quarter valued at about $173,000. Finally, Sphera Funds Management LTD. acquired a new position in shares of Tenax Therapeutics during the third quarter valued at about $101,000. Institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.